File:Not all tissues receiving notochord-emitted signals are affected by U0126 treatment.jpg
From Wikimedia Commons, the free media repository
Jump to navigation
Jump to search
Size of this preview: 800 × 507 pixels. Other resolutions: 320 × 203 pixels | 640 × 405 pixels | 1,024 × 649 pixels | 1,280 × 811 pixels | 2,362 × 1,496 pixels.
Original file (2,362 × 1,496 pixels, file size: 1.48 MB, MIME type: image/jpeg)
File information
Structured data
Captions
Summary
[edit]DescriptionNot all tissues receiving notochord-emitted signals are affected by U0126 treatment.jpg | Zebra fish. Not all tissues receiving notochord-emitted signals are affected by U0126 treatment. A-D: flk-1 expression reveals defects in dorsal aorta differentiation (green arrow in panel D) and in the sprouting of intersomitic vessels. Notice that both lack of sprouting (yellow arrows) and double sprouting (red arrow) occurs in U0126-treated embryos (D). Expression of the early muscle differentiation marker myoD is normal in treated embryos (E, F) but the muscle pioneer cell marker eng2 is upregulated (G, H). The floor plate of the neural tube differentiates normally (I, J and also Fig. 4/M–X). Isl-1 expression shows that the sensory Rohon-Beard neurons and motoneurons both develop properly in treated embryos (K, L) |
Date | |
Source | https://bmcdevbiol.biomedcentral.com/articles/10.1186/1471-213X-8-42#Fig5 https://bmcdevbiol.biomedcentral.com/articles/10.1186/1471-213X-8-42 Hawkins, T.A., Cavodeassi, F., Erdélyi, F. et al. The small molecule Mek1/2 inhibitor U0126 disrupts the chordamesoderm to notochord transition in zebrafish. BMC Dev Biol 8, 42 (2008). |
Author | Hawkins, T.A., Cavodeassi, F., Erdélyi, F. et al. |
This file, which was originally posted to an external website, has not yet been reviewed by an administrator or reviewer to confirm that the above license is valid. See Category:License review needed for further instructions.
|
Rights and permissions
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Licensing
[edit]This file is licensed under the Creative Commons Attribution 2.0 Generic license.
- You are free:
- to share – to copy, distribute and transmit the work
- to remix – to adapt the work
- Under the following conditions:
- attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
File history
Click on a date/time to view the file as it appeared at that time.
Date/Time | Thumbnail | Dimensions | User | Comment | |
---|---|---|---|---|---|
current | 00:15, 25 April 2024 | 2,362 × 1,496 (1.48 MB) | Rasbak (talk | contribs) | ||
23:56, 24 April 2024 | 1,200 × 760 (455 KB) | Rasbak (talk | contribs) | {{Information |description=Not all tissues receiving notochord-emitted signals are affected by U0126 treatment. A-D: flk-1 expression reveals defects in dorsal aorta differentiation (green arrow in panel D) and in the sprouting of intersomitic vessels. Notice that both lack of sprouting (yellow arrows) and double sprouting (red arrow) occurs in U0126-treated embryos (D). Expression of the early muscle differentiation marker myoD is normal in treated embryos (E, F) but the muscle pioneer cell... |
You cannot overwrite this file.
File usage on Commons
There are no pages that use this file.
Hidden categories: